RecruitingNot ApplicableNCT07811765

Preconception vs First-Trimester Screening and Treatment for Iron Deficiency Anemia: A Cluster Randomized Trial

Effect of Anemia Intervention Timing (Preconception vs. First Trimester) on the Control of Iron Deficiency Anemia in the Third Trimester: A Cluster Randomized Controlled Trial

Sponsor

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Enrollment

960 participants

Start Date

Jul 10, 2026

Study Type

INTERVENTIONAL

Conditions

Iron-Deficiency Anemia

Summary

This cluster randomized trial compares preconception with early-pregnancy anemia screening and iron supplementation, assessing late pregnancy iron deficiency anemia and maternal and infant outcomes.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Early-Pregnancy Anemia Screening and Treatment Strategy and Preconception Anemia Screening and Treatment Strategy for people with iron-deficiency anemia. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERPreconception Anemia Screening and Treatment Strategy

Women planning pregnancy within 6 months undergo hemoglobin, hemoglobin electrophoresis, and serum ferritin assessments before conception. Those with hemoglobin levels below 120 g/L and/or serum ferritin levels below 30 μg/L receive oral ferrous succinate (0.2 g twice daily) plus vitamin C, with scheduled hematologic monitoring.

OTHEREarly-Pregnancy Anemia Screening and Treatment Strategy

Women with a singleton pregnancy at 12 weeks' gestation who have hemoglobin levels below 110 g/L and/or serum ferritin levels below 30 μg/L will receive oral ferrous succinate (0.2 g twice daily) plus vitamin C, with scheduled hematologic monitoring